HUE044632T2 - Antitestek és endoglikozidázok kombinált terápiás alkalmazása - Google Patents

Antitestek és endoglikozidázok kombinált terápiás alkalmazása

Info

Publication number
HUE044632T2
HUE044632T2 HUE13701871A HUE044632T2 HU E044632 T2 HUE044632 T2 HU E044632T2 HU E13701871 A HUE13701871 A HU E13701871A HU E044632 T2 HUE044632 T2 HU E044632T2
Authority
HU
Hungary
Prior art keywords
endoglycosidases
antibodies
therapeutic use
combined therapeutic
combined
Prior art date
Application number
Other languages
English (en)
Inventor
Matthew David Max Crispin
Christopher Neil Scanlan
Original Assignee
Immago Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immago Biosystems Ltd filed Critical Immago Biosystems Ltd
Publication of HUE044632T2 publication Critical patent/HUE044632T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
HUE13701871 2012-01-26 2013-01-25 Antitestek és endoglikozidázok kombinált terápiás alkalmazása HUE044632T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201201314A GB201201314D0 (en) 2012-01-26 2012-01-26 Composition

Publications (1)

Publication Number Publication Date
HUE044632T2 true HUE044632T2 (hu) 2019-11-28

Family

ID=45840985

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13701871 HUE044632T2 (hu) 2012-01-26 2013-01-25 Antitestek és endoglikozidázok kombinált terápiás alkalmazása

Country Status (17)

Country Link
US (4) US20150125443A1 (hu)
EP (1) EP2806892B1 (hu)
JP (1) JP6249962B2 (hu)
CN (2) CN104519911B (hu)
CY (1) CY1122060T1 (hu)
DK (1) DK2806892T3 (hu)
ES (1) ES2728290T3 (hu)
GB (1) GB201201314D0 (hu)
HR (1) HRP20191022T1 (hu)
HU (1) HUE044632T2 (hu)
IN (1) IN2014DN06722A (hu)
LT (1) LT2806892T (hu)
PL (1) PL2806892T3 (hu)
PT (1) PT2806892T (hu)
SI (1) SI2806892T1 (hu)
TR (1) TR201908367T4 (hu)
WO (1) WO2013110946A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
GB201318490D0 (en) * 2013-10-18 2013-12-04 Genovis Ab Method
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-cd20 글리코항체 및 이의 용도
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
KR102576850B1 (ko) * 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
CA2950433A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
JP6752203B2 (ja) * 2015-07-16 2020-09-09 第一三共株式会社 新規EndoS変異酵素
EP3407914A4 (en) * 2016-01-27 2019-08-07 MedImmune, LLC METHOD FOR OBTAINING ANTIBODIES WITH DEFINED GLYCOSILATION PATTERN
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2017217344A1 (ja) * 2016-06-17 2017-12-21 SonoCore株式会社 分子標的薬バブルおよび分子標的薬バブルの製造方法
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN110151987B (zh) * 2018-02-11 2023-10-13 汕头大学医学院 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途
US20230049145A1 (en) * 2019-12-12 2023-02-16 Fresenius Kabi Deutschland Gmbh Glycosylated polypeptides
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
WO2021244628A1 (zh) * 2020-06-05 2021-12-09 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
CN113769058A (zh) * 2020-06-10 2021-12-10 上海宝济药业有限公司 一种药物组合及其应用
CN115515631A (zh) * 2020-09-21 2022-12-23 上海宝济药业有限公司 一种药物组合及其应用
JPWO2022124096A1 (hu) * 2020-12-11 2022-06-16
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US20040136986A1 (en) 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
CA2819867A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
ATE353651T1 (de) 2002-07-15 2007-03-15 Janssen Pharmaceutica Nv 3-furylanaloga von toxoflavin als kinaseinhibitoren
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
DK2190984T3 (da) * 2007-09-14 2013-12-02 Genovis Ab Fremgangsmåder og kits til oprensning og påvisning af glycosyleret IgG
KR102576850B1 (ko) * 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법

Also Published As

Publication number Publication date
JP6249962B2 (ja) 2017-12-20
US20170274070A1 (en) 2017-09-28
CY1122060T1 (el) 2020-11-25
SI2806892T1 (sl) 2019-08-30
IN2014DN06722A (hu) 2015-05-22
US20200345844A1 (en) 2020-11-05
EP2806892A1 (en) 2014-12-03
CN104519911A (zh) 2015-04-15
GB201201314D0 (en) 2012-03-07
TR201908367T4 (tr) 2019-06-21
US20150125443A1 (en) 2015-05-07
CN108619509A (zh) 2018-10-09
EP2806892B1 (en) 2019-03-06
US20230398212A1 (en) 2023-12-14
PL2806892T3 (pl) 2019-09-30
PT2806892T (pt) 2019-06-17
CN104519911B (zh) 2018-07-17
HRP20191022T1 (hr) 2019-09-06
JP2015511223A (ja) 2015-04-16
LT2806892T (lt) 2019-07-25
WO2013110946A1 (en) 2013-08-01
DK2806892T3 (da) 2019-06-11
ES2728290T3 (es) 2019-10-23

Similar Documents

Publication Publication Date Title
LT2806892T (lt) Kombinuota terapija, panaudojant antikūnus ir endoglikozidazes
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
HK1202123A1 (en) Human antibodies to fel d1 and methods of use thereof fel d1
ZA201408236B (en) Anti-ly6e antibodies and immunoconjugates and methods of use
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1209432A1 (en) Anti-jagged antibodies and methods of use
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids -mif
HK1206249A1 (en) Human autotaxin antibodies and methods of use (autotaxin)
HK1206985A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics -mif
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
EP2924046A4 (en) NEW COMPLEX AND USE